sábado, 15 de novembro de 2014

Beats by Dr. Dre rolls out new Bluetooth wireless headphones

 

Beats unveiled its first product in the Apple era, the Bluetooth-enabled Solo2 headphones

Beats unveiled its first product in the Apple era, the Bluetooth-enabled Solo2 headphones

The tech world has had an eye fixed on the Beats by Dr. Dre audio brand since Apple acquired it back in July. We're now getting our first glimpse of the Apple-owned Beats, as the Dr. Dre stable has just announced its first new product post-purchase just in time for the holidays: the Solo2 Wireless on-ear headphones.

The Solo2 headphones, pricing around $300, follow on the heels of the market leading Solo model, according to Beats Electronics/Apple. What is most noted for being new with this release is the integration of wireless Bluetooth functionality, which lets one enjoy streaming audio up to 30 feet away from a compatible device, such as an iPhone.

Control for the headphones is built into the “b” and volume buttons on one of the ear cups. From here you can take phone calls, change songs and manipulate the music volume. There’s also an integrated microphone for use when a call does come in, allowing for nearly hands-free operation.

The headphones have a claimed 12 hours wireless usage time, and can be recharged in about 2 hours by plugging in an included USB charging cable. This cable also allows for usage even when the battery is drained when connected to an external power supply. Should you need to know the status of your battery, tapping the power button will light up a series of LEDs to let you know how much charge is left.

Physically speaking, the Solo2 model sports a curved design, which supposedly helps to improve comfort. This is augmented by padded, pivoting ear cups said to offer passive noise blocking. Body color choices will include red, white, black and blue when it becomes available this month.

Source: Beats by Dr. Dre

 

Unshackling The Gold Standard

 

Tue, 11/11/2014 - 9:09am

Chris Petty, VP of Business Development, 908 Devices

 

Image: 908 Devices

Image: 908 Devices

Demand for mass spectrometry continues to rise. According to a recent Marketsandmarkets report, the global mass spectrometry market is expected to reach $5.9 billion by 2018. That’s a healthy compounded annual growth rate of 8.7%. Since its earliest demonstration more than 100 years ago, this analytical technique has become known as the “gold standard” of chemical analysis and can be found in virtually every laboratory around the globe performing a broad range of chemical analyses. Mass spectrometry uniquely combines high sensitivity and excellent selectivity to make it suitable for myriad applications across the life sciences, safety and security, environmental and energy sectors, to name a few. This breadth of utility drives much interest in unshackling mass spec from the laboratory.

The evolution of the mass spectrometer to more powerful systems with ever-increasing sensitivity and dizzying resolving capability—the horse power race if you will—should continue to unlock scientific discovery for years to come. Here however, we consider an orthogonal direction in development—portable devices that can bring analysis to the point of need. In considering this evolutionary path we see a strong influence from both miniaturization and consumerization trends.

As the mass spec community is able to achieve true portability—learning from the consumer world with the development of handheld smart devices that provide answers-on-the-go, chemical analysis will be dramatically changed.

Mass spectrometry: Yesterday and today
In the analytical sciences there’s a common image of using mass spectrometry: researchers in white coats analyzing spectra generated by a machine the size of a refrigerator. Because conventional mass spectrometers operate under extreme vacuum, they’re coupled with large pumps that are expensive, bulky, power hungry and extremely fragile. Together, the size, cost and fragility of conventional systems traditionally limited mass spectrometry to laboratory use. These powerhouse systems are designed to accommodate a wide variety of often-disparate needs, and this flexibility adds complexity in both operation and maintenance.

Several groups have explored hardening and form factor alterations to bring mass spec out of the central laboratory. Today’s transportable instruments, such as Agilent’s 5975T, still have the size and weight of laboratory systems (around 150 lbs), but are sufficiently hardened to be movable. While these systems remain relatively fragile and complex to use, they’re deployed in a range of mobile laboratories.

A few person-portable systems, or “luggables” as they are often referred, have been introduced within the last 20 years, enabling some mass spec analysis in the field. Considering successive generations of Inficon’s Hapsite instrument, first introduced in the mid-90s, or more recent offerings from Torion, it’s apparent that improvement to the form factor of luggable systems has currently plateaued around the size of a small suitcase, weighing roughly 35 lbs or more.

The introduction of these luggable mass spec systems was an undeniable step forward and an important demonstration of demand for analysis in the field. However, widespread adoption is still limited by the remaining complexity and relative fragility of these iterations. It’s illustrative to consider other analytical techniques such as XRF, Raman and FTIR, each of which initially escaped the laboratory in luggable form factors, but ultimately gained broad adoption with the rugged, purpose-built handheld systems we see in field applications today.

The development of truly handheld mass spectrometry tools will have even more significant impact.

Consumerization and tiny new tools
Thanks to the evolution of consumer-driven mobile technology, we’ve all become accustomed to accessing data and answers immediately. More subtly, advances in ergonomic design and user interface construction are driven by the need to put complex technologies in the hands of consumers, which has influenced the expectation that technology should provide answers at the push of a button.

This consumer culture shift has contributed to a new wave of analytical instrumentation that has changed the course for many established industries.

Within the past few decades there has been remarkable growth in the demand for purpose-built and user-centric analytical tools. The introduction of handheld XRF, Raman, NIR and FTIR technologies created a paradigm shift in diverse applications from safety and security to mining and metals analysis. These disruptive developments haven’t only changed the way in which materials are analyzed, they have redefined the capabilities of the non-technical user. These advanced technologies have been packaged in handheld form factors weighing less than 5 lbs and performing very specific jobs for users with no interest in knowing how analytical instruments work or what’s happening inside. They simply have a job to get done and want answers.

Until recently, mass spec has yet to join the ranks of this handheld analytical revolution. It has taken technology breakthroughs and a new approach to mass spec implementation to make the leap to truly handheld operation. A new technique called high-pressure mass spectrometry (HPMS), commercialized by Boston-based 908 Devices, is powering mass spec tools that are handheld, battery operated and purpose built for specific applications. HPMS not only allows for several key components of the mass spectrometer to be miniaturized, it also removes the need for large, cumbersome vacuum pumps that limit conventional mass spec approaches.

The future: What’s next?
While transportable and luggable systems have moved mass spectrometry out of the central laboratory, they’re analogous to early computers or the first mobile phones: remarkable as initial breakthroughs, but still too large, expensive, slow and fragile for true widespread adoption. Present-day consumer expectations for mobile technology do indeed set the bar for an analytical industry that strives to provide answers when and where they’re needed. Today’s portable analytical tools need to go beyond simply being small; they must be accessible and usable by anyone regardless of education or skill level and provide trusted answers in real time.

Looking ahead, the future of mass spec is bright. In parallel with advances in traditional laboratory systems, developments such as HPMS and miniaturization will see the gold standard liberated from the laboratory and continuing to evolve from complicated to common.

www.rdmag.com

Snap 2014-11-15 at 20.11.10

Evolution of NIR Spectroscopy: Past, Present and Future

 

Fri, 11/14/2014 - 4:04pm

Joe Siddall, TI DLP Embedded Products Program Manager

 

Typical NIR spectroscopy applications. Images: Texas Instruments

Typical NIR spectroscopy applications. Images: Texas Instruments Near-infrared (NIR) spectrometers have been around for over 60 years, yet only a small fraction of the population is familiar with these dependable tools. It’s astounding that NIR spectroscopy does so much for so many people who have never heard the word “spectrometer.” NIR spectrometers help a diverse set of users make decisions in their daily jobs.

Multiple industries including food, agriculture, forensics, arson detection, pharmaceuticals, petroleum and medical depend on critical information provided by spectrometers. NIR spectrometers measure energy reflected from, or transmitted through, a material sample. This technique allows people to understand the types of molecules within the sample. In a sense, NIR spectrometers look for the molecular “fingerprint” of a substance.

NIR spectroscopy: The past
Early spectrometers were often large, bulky, sensitive instruments with moving parts. Illumination sources were dispersed into their subcomponent wavelengths by prisms or gratings. The gratings rotated in small increments under hand control for each measurement point on the desired spectrum. Data was constructed into a spectral plot for each sample measured. Then, comparisons to references and other samples were made by hand. These early spectrometers remained stationary in a laboratory, and were rarely moved once installed. 

The 1970s heralded the advent of the microprocessor in spectroscopy, both for controlling the spectrometer and for processing the resulting data. The semiconductor industry picked up its pace from the 1970s through the 2000s. This revolutionized microprocessors and computers to better control spectrometers and process spectrum data. The advent of analog-to-digital converters allowed sampling of spectrum data under processor control.

The present

 

Snap 2014-11-15 at 20.08.41

Rotating grating (above) and DMD (below) architectures 

Today, there are six architectures commonly used for NIR spectrometers:

  • Fixed filters: These instruments measure at a fixed number of wavelengths, each corresponding to an optical filter located on a wheel. Readings are taken as the wheel steps from filter to filter. 
  • Rotating grating/prism: These instruments use a motor to move a grating’s dispersed output (wavelengths) across a single point detector. 
  • FT-NIR: These instruments use the Fourier transform properties of the Michelson interferometer technique. They have moving mirrors to create interference patterns which can be mathematically related to a spectrum.       
  • Linear array detector: These instruments use a grating to disperse wavelengths across a 1-D linear pixel array, which can have upwards of 256 or 512 elements.
  • Linear variable filter: These instruments use a variable filter element in front of a linear array detector which allows specific wavelengths to impact each pixel element.
  • DLP technology: The digital micromirror device (DMD) directs light dispersed on it by a grating to a single pixel detector. The DMD is programmable and flexible, allowing wavelengths to be sampled in any order or at different resolutions. This can be done within a single scan.

Current NIR spectrometers are far ahead of their predecessors, leveraging microprocessor control, precision A/D sampling and computerized spectrum calculation with statistical analysis. Use models can vary across architectures:

  • Laboratory use: These are typically large, high-precision, general-purpose instruments. The computers processing spectral data can be internal or remotely located and connected via Ethernet or USB. They process enormous amounts of data and make comparisons to a distributed reference library in seconds. 
  • Portable use: Portable NIR spectrometers look similar to small laboratory units, which are moveable and usually run off an AC 110-V supply or a 12-V supply with inverter. Often they’re bigger than a lunchbox and can sit on the tailgate of a truck for use in the field or industrial settings, like a farm or mine.
  • In-line use: These specialized units monitor factory environments and are typically use specific. A factory install can contain multiple spectrometers on an assembly line linked via Ethernet or wirelessly to a main control facility. 
  • Handheld use: There is a big focus on making handheld spectrometers which are truly mobile and user friendly. Current examples can be battery operated and are about the size of a large hand drill. The benefit is that they are truly portable and run off a built-in power supply for remote use.

DLP technology.

DLP technology.The future

The future of NIR spectrometry looks very bright. Traditionally, instruments have been large and expensive, housed in controlled laboratory environments and not typically available to the general public.  Use models have been determined mostly by the size and cost of this typical laboratory equipment. Technical improvements enabling size and cost reductions have made more recent generations of NIR spectrometers more portable and suitable for use in the field.

Thanks to the development of new detector and DLP technologies, the miniaturization supplied by the semiconductor industry and the advent of cloud-based computing, it’s easy to envision a future with mobile NIR spectrometers. Small, affordable, effective and user-friendly solutions can bring spectrometers to the public.

Newer technologies can enable disruptive spectrometer businesses. The massive popularity of smartphones now puts incredible computing power in the palm of your hand. NIR spectrometers can theoretically follow a similar size and cost curve, eventually moving measurements to the home or “personal use” model. It may not be called an “NIR spectrometer,” but future personal measurement devices may someday help families evaluate foods for ripeness, detect food allergens, confirm purity of expensive olive oils, assist in medical monitoring or check automotive fluids. The inevitable drive towards smaller, more powerful NIR spectrometers truly opens up a vast spectrum of future applications.

Snap 2014-11-15 at 20.11.10

www.rdmag.com

One day, we may fill the tank with fungi fuel -- Science Nation

 

                                                 

Over his 50-year career, Montana State University plant pathologist Gary Strobel has traveled to all seven continents to collect samples of endophytes from remote and sometimes dangerous places. Endophytes are microorganisms--bacteria and fungi--that live within the living tissue of a plant. With support from NSF, Strobel, engineer Brent Peyton and their team at Montana State University have discovered that endophytes have the ability to make diesel-like fuel. One hydrocarbon-producing fungus comes from the Ulmo tree of Patagonia. Another is a citrus fungus from Florida. And, amazingly, it takes the team just a few weeks to create the fuel.

Original air date: Sept. 23, 2013. Credit: National Science Foundation

Could liposomes be the answer to our antibiotic crisis?

 

A new compound could help end our over-reliance on antibiotics to fight bacterial infectio...

A new compound could help end our over-reliance on antibiotics to fight bacterial infections (Photo: Shutterstock)

It’s no secret we are facing an antibiotic crisis. Overuse has caused widespread antibiotic resistance, leading the World Health Organisation to declare we are "headed for a post-antibiotic era, in which common infections and minor injuries which have been treatable for decades can once again kill." Scientists from the University of Bern have developed a new non-antibiotic compound that treats severe bacterial infections and avoids the problem of bacterial resistance.

We have a lot to thank antibiotics for. Before the discovery of penicillin 90 years ago pneumonia, tuberculosis, or even an infected cut could be fatal. And today, many of our routine surgical procedures are dependent on the ability to fight infections with antibiotics.

However, up to half of antibiotic use in humans and much of antibiotic use in animals is unnecessary or inappropriate according to the Centers for Disease Control, and this overuse is the single most important factor leading to antibiotic resistance.

Although there have been many developments over the years, such as antibiotic "smart bombs", the difficulty has been eliminating bacteria without also promoting bacterial resistance. This has created a need to strive for non-antibiotic approaches, including "ninja polymers" and more natural treatments like raw honey and natural proteins.

This latest non-antibiotic compound developed by Eduard Babiychuk and Annette Draeger from the Institute of Anatomy, University of Bern, and tested by a team of international scientists, was created by engineering artificial nanoparticles made of lipids, "liposomes" that closely resemble the membrane of host cells.

In clinical medicine, liposomes are used to deliver specific medication into the body of patients. The scientists in Bern have created liposomes that act as bait, attracting bacterial toxins so they can be isolated and neutralized, thereby protecting host cells from a dangerous toxin attack. Without toxins, the bacteria are rendered defenseless and can be eliminated by the host's own immune system. Mice which were treated with the liposomes after experimental, fatal septicemia survived without additional antibiotic therapy.

"We have made an irresistible bait for bacterial toxins. The toxins are fatally attracted to the liposomes, and once they are attached, they can be eliminated easily without danger for the host cells," says Eduard Babiychuk who directed the study.

"Since the bacteria are not targeted directly, the liposomes do not promote the development of bacterial resistance", adds Annette Draeger.

The work has been published in Nature Biotechnology.

Source: University of Bern via AlphaGalileo

Share

New insight into common cause of blindness

 


Fluorescent staining of human macula (CFH is red, the FHL-1 protein is green).

Scientists at The University of Manchester have identified an important new factor behind one of the major causes of blindness, which they hope could lead to new treatments.

Age-related Macular Degeneration (AMD) is the major cause of blindness in the western world, affecting around 50 million people. It has been shown that sufferers are genetically predisposed to develop the condition.

One of the most important risk associated genes is called complement factor H (CFH). This encodes a protein called factor H (FH) that is responsible for protecting our eyes from attack by part of our immune system, called the complement system. FH achieves this by sticking to tissues, and when it is present in sufficient quantities it prevents the complement system from causing any damage.

Scientists from the Faculty of Medical and Human Sciences have now discovered that the protein factor H is not the main regulator of immunity in the back of the eye, instead it is a different protein that is made from the same CFH gene. This is called factor H-like protein 1 (FHL-1). The research has been published in the Journal of Immunology.

Dr Simon Clark, a Medical Research Council Career Development Fellow, led the research: "FHL-1 is a smaller version of FH, in fact it is about a third of the size. However, it has all the necessary components to regulate the immune system and is still subject to the genetic alterations that affect AMD risk. Our research has shown that the FHL-1, because it is smaller than FH, can get into structures of the back of the eye which cannot be reached by the larger FH."

He continues: "Therefore, this research suggests that it is FHL-1 rather than FH which protects the back of the eye from immune attack and that insufficient FHL-1 in the back of the eye may result in inflammation that eventually results in vision loss from AMD. FHL-1, although very similar to FH in many ways, does have a totally unique 'tail' structure at its end. This tail seems to mediate how FHL-1 binds tissue. As such, this work has identified a new target for therapeutics aimed at readdressing immune imbalance in the eye, thereby preventing or slowing down AMD."

Dr Clark successfully identified FHL-1 in human eye tissue that was donated with consent for research following removal of the corneas for transplantation.

He says: "There is no better way to understand and prevent blindness than to use actual human tissue."

 

 

Story Source:

The above story is based on materials provided by Manchester University. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. J. Clark, C. Q. Schmidt, A. M. White, S. Hakobyan, B. P. Morgan, P. N. Bishop. Identification of Factor H-like Protein 1 as the Predominant Complement Regulator in Bruch's Membrane: Implications for Age-Related Macular Degeneration. The Journal of Immunology, 2014; 193 (10): 4962 DOI: 10.4049/%u200Bjimmunol.1401613

Nonsmokers in automobiles are exposed to significant secondhand smoke

 


Nonsmokers sitting in an automobile with a smoker for one hour had markers of significantly increased levels of carcinogens and other toxins in their urine, indicating that secondhand smoke in motor vehicles poses a potentially major health risk according to a groundbreaking study led by UC San Francisco researchers.

The nonsmoking passengers showed elevated levels of butadiene, acrylonitrile, benzene, methylating agents and ethylene oxide. This group of toxic chemicals is "thought to be the most important among the thousands in tobacco smoke that cause smoking-related disease," said senior investigator Neal L. Benowitz, MD, a UCSF professor of medicine and bioengineering and therapeutic sciences and chief of the division of clinical pharmacology at San Francisco General Hospital and Trauma Center.

"Ours is the first study to measure exposure to these particular chemicals in people exposed to secondhand smoke," said Benowitz. "This indicates that when simply sitting in cars with smokers, nonsmokers breathe in a host of potentially dangerous compounds from tobacco smoke that are associated with cancer, heart disease and lung disease."

The scientists published their results on November 14, 2014 in the journal Cancer, Epidemiology, Biomarkers & Prevention published by the American Association for Cancer Research.

For the study, 14 nonsmokers each sat for one hour in the right rear passenger seat of a parked sport utility vehicle behind a smoker in the driver's seat. During that time, the smoker smoked three cigarettes. The front and rear windows were opened 10 centimeters, or almost four inches.

Before being exposed to the smoke and then eight hours afterward, the nonsmokers' urine was analyzed for biomarkers of nine chemical compounds found in cigarette smoke that are associated with cancer, cardiovascular disease and respiratory diseases. Seven biomarkers showed a significant increase following exposure to secondhand smoke.

"This tells us that people, especially children and adults with preexisting health conditions such as asthma or a history of heart disease should be protected from secondhand smoke exposure in cars," said lead author Gideon St. Helen, PhD, a postdoctoral researcher in the UCSF Department of Medicine.

The scientists cautioned that the research might not represent smoking situations in most cars because the stationary vehicle used in the research would provide less ventilation than a moving car.

"Nonetheless, the air samples we took were similar in makeup to those seen in previous smoking studies that used closed cars and cars with different ventilation systems in operation," said St. Helen. "And so we believe that the general levels of risk to nonsmokers that we present is realistic."


Story Source:

The above story is based on materials provided by University of California - San Francisco. The original article was written by Elizabeth Fernandez. Note: Materials may be edited for content and length.


Journal Reference:

  1. Gideon St. Helen, Peyton Jacob III, Margaret Peng, Delia A. Dempsey, S. Katharine Hammond, and Neal L. Benowitz. Intake of Toxic and Carcinogenic Volatile Organic Compounds from Secondhand Smoke in Motor Vehicles. Cancer, Epidemiology, Biomarkers & Prevention, November 2014 DOI: 10.1158/1055-9965.EPI-14-0548

 

How to get teens, young adults with chronic conditions to take their medications

 

November 14, 2014

American Society of Nephrology (ASN)

Many young patients with chronic conditions don’t take their medications correctly, but two new studies point to ways to address such medication non-adherence. "Young adult patients are at a critical point in their educational, psychological, and professional development that will shape their future life. Increasing the survival of their transplants will lead to higher levels of education and employment rates, which will be financially beneficial to society," said one researcher.


Many young patients with chronic conditions don't take their medications correctly, but 2 new studies point to ways to address such medication non-adherence. The studies will be presented at ASN Kidney Week 2014 November 11-16 at the Pennsylvania Convention Center in Philadelphia, PA.

In one study, researchers led by Frederick Kaskel, MD, PhD (Albert Einstein College of Medicine) and Oleh Akchurin, MD (Weill Cornell College of Medicine) looked to see how young patients are using smart phones to help them take their medications. They surveyed patients at a pediatric kidney clinic. The researchers found that the majority of teens continued to use traditional techniques of improving medication adherence, such as filling pillboxes and incorporating medications into their daily routines. Ninety-three percent of surveyed teens had a smart phone in their personal possession, but only 29% were aware about medical mobile apps, even though 50% said they used cell phones for some kind of reminders to take medications. Boys were more likely to use cell phones to remember to take medications than girls and the prevalence of 100% self-reported medication adherence was higher in teens who used cell phones for reminders.

"This study demonstrates that a number of inner city teenagers with kidney disorders are utilizing their cell phones for the management of medication administration even in the absence of organized program promoting such use," said Dr. Akchurin. "Further research efforts are required to fully describe the contemporary pattern of smart phone-based technology use in medication adherence in this population in order to allow health care providers a meaningful way to incorporate these existing practices into daily clinical activity."

In another study of kidney transplant recipients aged 17 to 30 years, Jeroen Bastiaan van der Net, MD, PhD, Paul Harden, FRCP (Oxford University Hospital, in the UK) and their colleagues found that patients who were involved in a dedicated Young Adult Service were 4 times less likely to experience loss of function of their donated organ than young adult patients who were not involved in this service. Key features of a successful Young Adult Service are a dedicated team comprised of a key physician, nurse practitioner, and youth worker; Young Adult Clinics for patients within a community setting such as a sports club or university; and peer interactions through social events such as bowling or other activities.

"Young adult patients are at a critical point in their educational, psychological, and professional development that will shape their future life. Increasing the survival of their transplants will lead to higher levels of education and employment rates, which will be financially beneficial to society," said Dr. Harden.


Story Source:

The above story is based on materials provided by American Society of Nephrology (ASN). Note: Materials may be edited for content and length.


 

Sleep apnea may contribute to kidney disease progression

 

November 14, 2014

American Society of Nephrology (ASN)

Sleep apnea may accelerate kidney function decline in diabetic patients with kidney disease, a study shows. "This study shows that a high-risk score for obstructive sleep apnea is common in non-dialysis chronic kidney disease (CKD) patients with diabetic nephropathy and is associated with more rapid loss of renal function," the investigators concluded. "This simple approach identifies patients at higher risk of CKD progression."


Sleep apnea may accelerate kidney function decline in diabetic patients with kidney disease, according to a study that will be presented at ASN Kidney Week 2014 November 11-16 at the Pennsylvania Convention Center in Philadelphia, PA.

Type 2 diabetes often contributes to the development of chronic kidney disease (CKD). Because obstructive sleep apnea is common in patients with type 2 diabetes, investigators wonder whether disordered sleep might play a role in the link between diabetes and kidney dysfunction. To investigate, researchers led by Roberto Pisoni, MD (Medical University of South Carolina) analyzed information on 56 patients with diabetes and CKD who had undergone screening for obstructive sleep apnea through the use of a questionnaire.

The researchers found that 61% of patients had a high score on the questionnaire. These individuals had a significantly lower level of kidney function than those with a low score.

"This study shows that a high-risk score for obstructive sleep apnea is common in non-dialysis CKD patients with diabetic nephropathy and is associated with more rapid loss of renal function," the investigators concluded. "This simple approach identifies patients at higher risk of CKD progression."


Story Source:

The above story is based on materials provided by American Society of Nephrology (ASN). Note: Materials may be edited for content and length.


 

Crucial mechanism driving colliding epidemics of smoking, TB unlocked by scientists

 


TB is an infectious disease that kills 1.5 million people each year, and smoking is the biggest driver of the global TB epidemic. Medical scientists at Trinity College Dublin and St James's Hospital in Ireland have unlocked the mechanism underlying the connection between smoking and Tuberculosis (TB). This discovery will considerably strengthen anti-smoking efforts to control TB and uncovers new therapy and vaccine options for TB. Their research has just been published in the top respiratory Journal, the American Journal of Respiratory and Critical Care Medicine. The research was funded by the Health Research Board (HRB) and The Royal City of Dublin Hospital Trust.

Tuberculosis spreads from person to person by inhaling infected droplets made when the TB sufferer coughs. The World Health Organization has designated TB a global emergency. Nine million people fall ill with TB each year, and it is the greatest killer worldwide due to a single bacterial infection. Many countries have recurring outbreaks and multi-drug resistant TB cases.

After infection most people do not become ill with TB, but immunosuppressed patients are susceptible. Smoking increases a person's susceptibility to infection by TB, risk of recurrence, mortality and persistent infectiousness. However, until now the exact reason or mechanism behind this connection between smoking and TB has been unknown.

The research team conducted the study with smokers, ex-smokers and non-smokers attending the bronchoscopy suite at St James's Hospital in Dublin. They found that the white blood cells located in the lungs of smokers and ex-smokers, which are responsible for fighting infections, showed a weakened response to the TB infection. In the smoker's lungs, these cells malfunction, and fail to make the chemical messengers that would normally fight the TB bacteria. In fact, the researchers found that these cells suppress the lungs' immunity after infection, which gives the TB bacteria a chance to take over.

Joseph Keane is Professor of Medicine at Trinity and St James's Hospital, HRB Clinician Scientist, and the senior author of the study. He said: "TB remains a huge global health problem, affecting millions worldwide. It has been known for some time that smokers are more susceptible to getting TB and nearly 80% of the world's one billion smokers live in countries of high TB prevalence. Therefore, while HIV is a key driver of the disease, numerically, smoking is more prevalent than HIV, making smoking the biggest global driver of the TB epidemic."

"This study provides evidence which explains the link between smoking and TB and should considerably strengthen anti-smoking efforts to control TB. However, the widespread emergence of multi-drug resistance TB means we badly need new therapy and vaccine options for TB. We are already applying the findings of this study to develop new treatment options."


Story Source:

The above story is based on materials provided by Trinity College Dublin. Note: Materials may be edited for content and length.


Journal Reference:

  1. Seónadh M O'Leary, Michelle M Coleman, Wui Mei Chew, Colette Morrow, Anne Marie McLaughlin, Laura E Gleeson, Mary P O'Sullivan, Joseph Keane. Cigarette Smoking Impairs Human Pulmonary Immunity toMycobacterium tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2014; 141112083842005 DOI: 10.1164/rccm.201407-1385OC